Drug Profile
GLPG 2534
Alternative Names: GLPG2534Latest Information Update: 04 Sep 2023
Price :
$50
*
At a glance
- Originator Galapagos NV
- Class Skin disorder therapies
- Mechanism of Action Undefined mechanism
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
Highest Development Phases
- Discontinued Atopic dermatitis
Most Recent Events
- 04 Sep 2023 Discontinued - Preclinical for Atopic dermatitis in Belgium (unspecified route) (Galapagos pipeline, September 2023)
- 28 Jul 2020 No recent reports of development identified for preclinical development in Atopic-dermatitis in Belgium
- 31 Dec 2017 Galapagos NV has a pending PCT application, and pending patent applications in Taiwan and other countries, related to GLPG 2534